# Ultralife Corp: financial statements, quarterly

ULBI · Nasdaq · CIK 875657 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ulbi.md) · [Financials](/companies/ulbi/financials.md) · [Filings](/companies/ulbi/filings.md) · [Insiders](/companies/ulbi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ulbi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [39.5](/filings/0001437749-24-034608.md) | [44.5 d](/filings/0001437749-25-010360.md) | [41.9](/filings/0001437749-25-016140.md) | [43.0](/filings/0001437749-25-025484.md) | [35.7](/filings/0001437749-25-035475.md) | [43.9 d](/filings/0001437749-26-009385.md) | [50.7](/filings/0001437749-26-015750.md) | [48.6](/filings/0001437749-26-026432.md) | [43.4](/filings/0001437749-25-035475.md) | [48.5 d](/filings/0001437749-26-009385.md) | [47.4](/filings/0001437749-26-015750.md) | [47.9](/filings/0001437749-26-026432.md) |
| Cost of revenue | $m | [29.7](/filings/0001437749-24-034608.md) | [33.1 d](/filings/0001437749-25-010360.md) | [30.5](/filings/0001437749-25-016140.md) | [31.4](/filings/0001437749-25-025484.md) | [27.0](/filings/0001437749-25-035475.md) | [33.3 d](/filings/0001437749-26-009385.md) | [38.0](/filings/0001437749-26-015750.md) | [37.0](/filings/0001437749-26-026432.md) | [33.8](/filings/0001437749-25-035475.md) | [36.4 d](/filings/0001437749-26-009385.md) | [37.3](/filings/0001437749-26-015750.md) | [34.1](/filings/0001437749-26-026432.md) |
| Gross profit | $m | [9.8](/filings/0001437749-24-034608.md) | [11.4 d](/filings/0001437749-25-010360.md) | [11.5](/filings/0001437749-25-016140.md) | [11.6](/filings/0001437749-25-025484.md) | [8.7](/filings/0001437749-25-035475.md) | [10.6 d](/filings/0001437749-26-009385.md) | [12.7](/filings/0001437749-26-015750.md) | [11.6](/filings/0001437749-26-026432.md) | [9.6](/filings/0001437749-25-035475.md) | [12.1 d](/filings/0001437749-26-009385.md) | [10.1](/filings/0001437749-26-015750.md) | [13.9](/filings/0001437749-26-026432.md) |
| Research and development | $m | [1.9](/filings/0001437749-24-034608.md) | [1.9 d](/filings/0001437749-25-010360.md) | [1.8](/filings/0001437749-25-016140.md) | [2.0](/filings/0001437749-25-025484.md) | [2.1](/filings/0001437749-25-035475.md) | [2.4 d](/filings/0001437749-26-009385.md) | [2.4](/filings/0001437749-26-015750.md) | [2.3](/filings/0001437749-26-026432.md) | [2.9](/filings/0001437749-25-035475.md) | [2.8 d](/filings/0001437749-26-009385.md) | [3.0](/filings/0001437749-26-015750.md) | [3.2](/filings/0001437749-26-026432.md) |
| Selling, general and administrative | $m | [5.8](/filings/0001437749-24-034608.md) | [5.9 d](/filings/0001437749-25-010360.md) | [5.7](/filings/0001437749-25-016140.md) | [5.6](/filings/0001437749-25-025484.md) | [6.1](/filings/0001437749-25-035475.md) | [6.7 d](/filings/0001437749-26-009385.md) | [6.9](/filings/0001437749-26-015750.md) | [7.0](/filings/0001437749-26-026432.md) | [7.7](/filings/0001437749-25-035475.md) | [7.7 d](/filings/0001437749-26-009385.md) | [7.4](/filings/0001437749-26-015750.md) | [7.2](/filings/0001437749-26-026432.md) |
| Operating income | $m | [2.1](/filings/0001437749-24-034608.md) | [3.6 d](/filings/0001437749-25-010360.md) | [4.1](/filings/0001437749-25-016140.md) | [3.9](/filings/0001437749-25-025484.md) | [0.5](/filings/0001437749-25-035475.md) | [1.5 d](/filings/0001437749-26-009385.md) | [3.4](/filings/0001437749-26-015750.md) | [2.3](/filings/0001437749-26-026432.md) | [(1.0)](/filings/0001437749-25-035475.md) | [(10.6) d](/filings/0001437749-26-009385.md) | [(0.2)](/filings/0001437749-26-015750.md) | [3.4](/filings/0001437749-26-026432.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.4](/filings/0001437749-24-034608.md) | [0.3 d](/filings/0001437749-25-010360.md) | [0.7](/filings/0001437749-25-016140.md) | [0.9](/filings/0001437749-25-025484.md) | [0.1](/filings/0001437749-25-035475.md) | [0.3 d](/filings/0001437749-26-009385.md) | [0.6](/filings/0001437749-26-015750.md) | [0.2](/filings/0001437749-26-026432.md) | [(0.5)](/filings/0001437749-25-035475.md) | [(2.8) d](/filings/0001437749-26-009385.md) | [(0.2)](/filings/0001437749-26-015750.md) | [0.5](/filings/0001437749-26-026432.md) |
| Net income | $m | [1.3](/filings/0001437749-24-034608.md) | [2.9 d](/filings/0001437749-25-010360.md) | [2.9](/filings/0001437749-25-016140.md) | [3.0](/filings/0001437749-25-025484.md) | [0.3](/filings/0001437749-25-035475.md) | [0.2 d](/filings/0001437749-26-009385.md) | [1.9](/filings/0001437749-26-015750.md) | [0.9](/filings/0001437749-26-026432.md) | [(1.2)](/filings/0001437749-25-035475.md) | [(7.4) d](/filings/0001437749-26-009385.md) | [(0.5)](/filings/0001437749-26-015750.md) | [2.5](/filings/0001437749-26-026432.md) |
| Diluted EPS | $ per share | [0.08](/filings/0001437749-24-034608.md) | not reported | [0.08](/filings/0001437749-25-016140.md) | [0.18](/filings/0001437749-25-025484.md) | [0.02](/filings/0001437749-25-035475.md) | not reported | [11.00](/filings/0001437749-26-015750.md) | [5.00](/filings/0001437749-26-026432.md) | [(0.07)](/filings/0001437749-25-035475.md) | not reported | [(3.00)](/filings/0001437749-26-015750.md) | [15.00](/filings/0001437749-26-026432.md) |
| Basic EPS | $ per share | [0.08](/filings/0001437749-24-034608.md) | not reported | [0.08](/filings/0001437749-25-016140.md) | [0.18](/filings/0001437749-25-025484.md) | [0.02](/filings/0001437749-25-035475.md) | not reported | [11.00](/filings/0001437749-26-015750.md) | [5.00](/filings/0001437749-26-026432.md) | [(0.07)](/filings/0001437749-25-035475.md) | not reported | [(3.00)](/filings/0001437749-26-015750.md) | [15.00](/filings/0001437749-26-026432.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.2](/filings/0001437749-23-029036.md) | [10.2](/filings/0001437749-25-010360.md) | [10.1](/filings/0001437749-24-013121.md) | [6.7](/filings/0001437749-24-023416.md) | [6.8](/filings/0001437749-24-034608.md) | [6.9](/filings/0001437749-26-009385.md) | [8.7](/filings/0001437749-25-016140.md) | [10.9](/filings/0001437749-25-025484.md) | [9.3](/filings/0001437749-25-035475.md) | [9.3](/filings/0001437749-26-009385.md) | [8.9](/filings/0001437749-26-015750.md) | [6.7](/filings/0001437749-26-026432.md) |
| Current assets | $m | [89.6](/filings/0001437749-23-029036.md) | [90.2](/filings/0001437749-25-010360.md) | [94.3](/filings/0001437749-24-013121.md) | [83.8](/filings/0001437749-24-023416.md) | [86.4](/filings/0001437749-24-034608.md) | [97.2](/filings/0001437749-26-009385.md) | [101](/filings/0001437749-25-016140.md) | [99.0](/filings/0001437749-25-025484.md) | [101](/filings/0001437749-25-035475.md) | [106](/filings/0001437749-26-026432.md) | [110](/filings/0001437749-26-015750.md) | [107](/filings/0001437749-26-026432.md) |
| Total assets | $m | [176](/filings/0001437749-23-029036.md) | [178](/filings/0001437749-25-010360.md) | [181](/filings/0001437749-24-013121.md) | [170](/filings/0001437749-24-023416.md) | [172](/filings/0001437749-24-034608.md) | [220](/filings/0001437749-26-009385.md) | [224](/filings/0001437749-26-015750.md) | [221](/filings/0001437749-26-026432.md) | [222](/filings/0001437749-25-035475.md) | [217](/filings/0001437749-26-026432.md) | [221](/filings/0001437749-26-015750.md) | [216](/filings/0001437749-26-026432.md) |
| Current liabilities | $m | [26.4](/filings/0001437749-23-029036.md) | [23.7](/filings/0001437749-25-010360.md) | [23.4](/filings/0001437749-24-013121.md) | [20.6](/filings/0001437749-24-023416.md) | [26.2](/filings/0001437749-24-034608.md) | [29.3](/filings/0001437749-26-009385.md) | [31.5](/filings/0001437749-25-016140.md) | [29.9](/filings/0001437749-25-025484.md) | [33.7](/filings/0001437749-25-035475.md) | [37.3](/filings/0001437749-26-026432.md) | [43.1](/filings/0001437749-26-015750.md) | [37.4](/filings/0001437749-26-026432.md) |
| Total liabilities | $m | [54.4](/filings/0001437749-23-029036.md) | [52.8](/filings/0001437749-25-010360.md) | [51.6](/filings/0001437749-24-013121.md) | [36.5](/filings/0001437749-24-023416.md) | [37.8](/filings/0001437749-24-034608.md) | [86.3](/filings/0001437749-26-009385.md) | [87.1](/filings/0001437749-25-016140.md) | [82.3](/filings/0001437749-25-025484.md) | [84.8](/filings/0001437749-25-035475.md) | [86.8](/filings/0001437749-26-026432.md) | [90.9](/filings/0001437749-26-015750.md) | [83.6](/filings/0001437749-26-026432.md) |
| Long-term debt | $m | [24.1](/filings/0001437749-23-029036.md) | [23.6](/filings/0001437749-25-010360.md) | [23.1](/filings/0001437749-24-013121.md) | [10.0](/filings/0001437749-24-023416.md) | [5.9](/filings/0001437749-24-034608.md) | [51.5](/filings/0001437749-26-009385.md) | [50.5](/filings/0001437749-25-016140.md) | [47.5](/filings/0001437749-25-025484.md) | [46.5](/filings/0001437749-25-035475.md) | [45.5](/filings/0001437749-26-026432.md) | [44.2](/filings/0001437749-26-015750.md) | [42.9](/filings/0001437749-26-026432.md) |
| Current portion of debt | $m | [2.0](/filings/0001437749-23-029036.md) | [2.0](/filings/0001437749-25-010360.md) | [2.0](/filings/0001437749-24-013121.md) | [2.0](/filings/0001437749-24-023416.md) | [2.0](/filings/0001437749-24-034608.md) | [2.8](/filings/0001437749-26-009385.md) | [3.1](/filings/0001437749-25-016140.md) | [3.4](/filings/0001437749-25-025484.md) | [3.8](/filings/0001437749-25-035475.md) | [4.1](/filings/0001437749-26-026432.md) | [3.4](/filings/0001437749-26-015750.md) | [1.8](/filings/0001437749-26-026432.md) |
| Shareholders' equity | $m | [122](/filings/0001437749-23-029036.md) | [125](/filings/0001437749-25-010360.md) | [129](/filings/0001437749-24-013121.md) | [133](/filings/0001437749-24-023416.md) | [134](/filings/0001437749-24-034608.md) | [134](/filings/0001437749-26-009385.md) | [136](/filings/0001437749-25-016140.md) | [138](/filings/0001437749-25-025484.md) | [137](/filings/0001437749-25-035475.md) | [130](/filings/0001437749-26-026432.md) | [130](/filings/0001437749-26-015750.md) | [133](/filings/0001437749-26-026432.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(889) d](/filings/0001437749-24-034608.md) | [2,432 d](/filings/0001437749-25-010360.md) | [(81.0)](/filings/0001437749-25-016140.md) | [8,925 d](/filings/0001437749-25-025484.md) | [4,746 d](/filings/0001437749-25-035475.md) | [3,046 d](/filings/0001437749-26-009385.md) | [3,368](/filings/0001437749-26-015750.md) | [5,935 d](/filings/0001437749-26-026432.md) | [198 d](/filings/0001437749-25-035475.md) | [1,489 d](/filings/0001437749-26-009385.md) | [2,256](/filings/0001437749-26-015750.md) | [1,188 d](/filings/0001437749-26-026432.md) |
| Capital expenditure | $k | [534 d](/filings/0001437749-24-034608.md) | [1,005 d](/filings/0001437749-25-010360.md) | [372](/filings/0001437749-25-016140.md) | [360 d](/filings/0001437749-25-025484.md) | [594 d](/filings/0001437749-25-035475.md) | [606 d](/filings/0001437749-26-009385.md) | [895](/filings/0001437749-26-015750.md) | [1,100 d](/filings/0001437749-26-026432.md) | [995 d](/filings/0001437749-25-035475.md) | [882 d](/filings/0001437749-26-009385.md) | [770](/filings/0001437749-26-015750.md) | [453 d](/filings/0001437749-26-026432.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.1](/filings/0001437749-23-029036.md) | [16.1](/filings/0001437749-24-013121.md) | [16.1](/filings/0001437749-24-023416.md) | [16.3](/filings/0001437749-24-034608.md) | [16.5](/filings/0001437749-25-016140.md) | [16.8](/filings/0001437749-25-025484.md) | [16.9](/filings/0001437749-25-035475.md) | [16.7](/filings/0001437749-26-015750.md) | [16.7](/filings/0001437749-26-026432.md) | [16.6](/filings/0001437749-25-035475.md) | [16.7](/filings/0001437749-26-015750.md) | [16.7](/filings/0001437749-26-026432.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,663,269 at 2026-08-03, from the cover of the [10-Q filed 2026-08-07](/filings/0001437749-26-026432.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.